These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 28736525)

  • 41. Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I.
    Penati R; Fumagalli F; Calbi V; Bernardo ME; Aiuti A
    J Inherit Metab Dis; 2017 Jul; 40(4):543-554. PubMed ID: 28560469
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autophagy and Lysosome Storage Disorders.
    Ren H; Wang G
    Adv Exp Med Biol; 2020; 1207():87-102. PubMed ID: 32671740
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proteostasis: bad news and good news from the endoplasmic reticulum.
    Noack J; Brambilla Pisoni G; Molinari M
    Swiss Med Wkly; 2014; 144():w14001. PubMed ID: 25144910
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gaucher disease and other storage disorders.
    Grabowski GA
    Hematology Am Soc Hematol Educ Program; 2012; 2012():13-8. PubMed ID: 23233555
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases.
    Li M
    Pediatr Ann; 2018 May; 47(5):e191-e197. PubMed ID: 29750286
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatments for lysosomal storage disorders.
    Lachmann R
    Biochem Soc Trans; 2010 Dec; 38(6):1465-8. PubMed ID: 21118108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FDA orphan drug designations for lysosomal storage disorders - a cross-sectional analysis.
    Garbade SF; Zielonka M; Mechler K; Kölker S; Hoffmann GF; Staufner C; Mengel E; Ries M
    PLoS One; 2020; 15(4):e0230898. PubMed ID: 32267884
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Disruption of the Ubiquitin-Proteasome System and Elevated Endoplasmic Reticulum Stress in Epilepsy.
    Poliquin S; Kang JQ
    Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327449
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emptying the stores: lysosomal diseases and therapeutic strategies.
    Platt FM
    Nat Rev Drug Discov; 2018 Feb; 17(2):133-150. PubMed ID: 29147032
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Lysosomes and lysosomal storage diseases].
    Germain DP
    J Soc Biol; 2002; 196(2):127-34. PubMed ID: 12360741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent advances in gene therapy for lysosomal storage disorders.
    Rastall DP; Amalfitano A
    Appl Clin Genet; 2015; 8():157-69. PubMed ID: 26170711
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lysosomal storage disorders: from biology to the clinic with reference to India.
    Sheth J; Nair A; Jee B
    Lancet Reg Health Southeast Asia; 2023 Feb; 9():100108. PubMed ID: 37383036
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders.
    Hou ZS; Ulloa-Aguirre A; Tao YX
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):611-624. PubMed ID: 29851355
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mitochondrial Dysfunction and Neurodegeneration in Lysosomal Storage Disorders.
    Plotegher N; Duchen MR
    Trends Mol Med; 2017 Feb; 23(2):116-134. PubMed ID: 28111024
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Autophagy-Lysosomal Pathways and Their Emerging Roles in Modulating Proteostasis in Tumors.
    Dong Z; Cui H
    Cells; 2018 Dec; 8(1):. PubMed ID: 30577555
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
    Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U
    J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mesenchymal Stem Cell-Based Therapy for Lysosomal Storage Diseases and Other Neurodegenerative Disorders.
    Issa SS; Shaimardanova AA; Valiullin VV; Rizvanov AA; Solovyeva VV
    Front Pharmacol; 2022; 13():859516. PubMed ID: 35308211
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Astrocytes and lysosomal storage diseases.
    Rama Rao KV; Kielian T
    Neuroscience; 2016 May; 323():195-206. PubMed ID: 26037807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alterations in membrane trafficking and pathophysiological implications in lysosomal storage disorders.
    Kuech EM; Brogden G; Naim HY
    Biochimie; 2016 Nov; 130():152-162. PubMed ID: 27664461
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enzyme replacement therapy for lysosomal storage diseases.
    Ohashi T
    Pediatr Endocrinol Rev; 2012 Oct; 10 Suppl 1():26-34. PubMed ID: 23330243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.